top of page

Clinical Trials in Progress Submissions

E-AHPBA 2023 Biennial Congress invites all interested individuals to submit abstracts for:


  • Have you organised a novel clinical trial pertaining to hepatopancreatobiliary diseases?

  • Are you currently accruing patients to an HPB trial?

  • Are you looking to connect with other institutions or investigators to broaden the accrual of a clinical trial in progress?

  • Have you early breaking results?


At the upcoming E-AHPBA 15th Biennial Congress to be held in Lyon, France from 6th - 9th June 2023, you will have an opportunity to present your work.

For the first time, the E-AHPBA Biennial Congress will include a session on Clinical Trials in Progress within their 2023 scientific programme. Following a competitive selection process, trials will be presented by their investigators with vibrant discussion and feedback. The session will provide a forum for sharing ideas, publicising trials seeking extramural participation, and promoting early results or findings.


Trials will be eligible for a brief Oral Presentation if they meet the following criteria:


  • Trials must be accruing or have patients under study follow-up

  • Trial results may not have been published at the time of presentation

  • Trials must be clinically focused and may include therapeutic, palliative, or diagnostic modalities

  • Preliminary results, outcomes, and endpoints may be presented


The deadline for submission of abstracts to be considered for this “Clinical Trials in Progress” session is 26th April 2023. There will not be any extension to this date.


The E-AHPBA Scientific Programme Committee look forward to these exciting updates in your ongoing clinical trials.


General Information

  • Trials should be submitted electronically through the link available on the Congress website.

  • The abstract must be written in English and limited to 250 words.

  • 1 Table and/or Image may be included in the abstract.

  • If you do not complete the submission process, your information will be held in “draft” until you return later to complete your submission. Please note that your trial must be fully submitted before the deadline of 26th April 2023 to be considered for the Congress.

  • Changes are possible until 26th April 2023 through your personal “My Submissions” page, which can be accessed with the link included in the electronic acknowledgement of receipt.

  • The submitting author will receive all correspondence concerning the trial and is responsible for informing the other co-authors of the abstract status.

  • Acknowledgement of abstract submission will be sent to the stated email address. If you do not receive the confirmation within 24 hours of submission, please contact E-AHPBA 2023 Abstract Department at

  • Notification of acceptance/rejection of the abstracts will be uploaded in advance of the Congress. Further details will be provided with the acceptance notifications.

  • Upon acceptance of the abstract, all presenting authors are expected to register and present their abstract in person at the Congress.

bottom of page